Ligand binding analysis for human α5β1 integrin: Strategies for designing new α5β1 integrin antagonists

Journal of Medicinal Chemistry

Volumn 48, Issue 13, 2005, Pages 4204-4207

  Marinelli, Luciana ^b   Meyer, Axel ^a   Heckmann, Dominik ^a   Lavecchia, Antonio ^b   Novellino, Ettore ^b   Kessler, Horst ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FIBRONECTIN; SJ 749; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL SURVIVAL; CROSS LINKING; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; LIGAND BINDING; MUTAGENESIS; NUCLEAR MAGNETIC RESONANCE; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; BINDING SITES; DRUG DESIGN; HUMANS; IMIDAZOLES; INTEGRIN ALPHA5BETA1; LIGANDS; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; PROTEIN SUBUNITS; SEQUENCE ALIGNMENT;

EID: 21244467582     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040224i     Document Type: Article

References (46)

1. Hynes R. O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110, 673-687.
2. Mousa, S. A. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Curr. Opin. Chem. Biol. 2002, 6, 534-541.
3. Pancioli, A. M.; Brott, T. G. Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in acute ischaemic stroke: scientific rationale and available evidence. CNS Drugs 2004, 18, 981-988.
4. (a) Brower, V. Tumor angiogenesis-new drugs on the block. Nat. Biotechnol. 1999, 17, 963-968.
5. (b) Arndt, T.; Arndt, U.; Reuning, U.; Kessler, H. Integrins in Angiogenesis: Implications for Tumor Therap. In Cancer Therapy: Molecular Targets in Tumor-Host Interactions; Weber, G. F., Ed., in press.
6. Brooks, P. C.; Clark, R. A.; Cheresh, D. A. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994, 264, 569-571.
7. Shimaoka, M.; Springer, T. A. Therapeutic antagonists and conformational regulation of integrin function. Nat. Rev. 2003, 2, 703-716.
8. Burke, P. A.; DeNardo, S. J.; Miers, L. A.; Lamborn, K. R.; Matzku, S.; DeNardo, G. L. Cilengitide targeting of alpha(v)-beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 2002, 62, 4263-4272.
9. Reynolds, L. E.; Wyder, L.; Lively, J. C.; Taverna, D.; Robinson, S. D.; Huang, X.; Sheppard, D.; Hynes, R. O.; Hodivala-Dikle, K. M. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat. Med. 2002, 8, 27-34.
10. Hynes, R. O. A reevaluation of integrins as regulators of angiogenesis. Nat. Med. 2002, 8, 918-921.
11. George, E. L.; Georges-Labouesse, E. N.; Patel-King, R. S.; Rayburn, H.; Hynes, R. O. Defect in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 1993, 119, 1079-1091.
12. (a) Kumar, C. C.; Malkowski, M.; Yin, Z.; Tanghetti, E.; Yaremko, B.; Nechuta, T.; Varner, J.; Liu, M.; Smith, E. M.; Neustadt, B.; Presta, M.; Armstrong, L. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res. 2001, 61, 2232-2238.
13. (b) Cheng, S. PCT Int. Appl. WO 9528426 A2 19951026, 1995.
14. Ruoslahti, E. PCT Int. Appl. WO 9514714 A1 19950601, 1995.
15. Cleary, P. P. PCT Int. Appl. WO 9856408 A2 19981217, 1998.
16. Labrecque, D. PCT Int. Appl. WO 2000075129 A1 20001214, 2000.
17. Ishikawa, M. PCT Int. Appl. WO 9952872 A1 19991021, 1999.
18. D'Souza, S. E.; Ginsberg, M. H.; Plow, E. F. Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif. Trends Biochem. Sci. 1991, 16, 246-250.
19. Xiong, J.-P.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M.; Goodman, S. L.; Arnaout, M. A. Crystal structure of the extracellular segment of integrin alphaV beta3 in complex with an Arg-Gly-Asp ligand. Science 2002, 296, 151-155.
20. Dechantsreiter, M. A.; Planker, E.; Mathä, B.; Lohof, E.; Hölzemann, G.; Jonczyk, A.; Goodman, S. L.; Kessler, H. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta-(3) integrin antagonists. J. Med. Chem. 1999, 42, 3033-3040.
21. (a) Mould, A. P.; Symonds, E. J. H.; Buckley, P. A.; Grossmann, J. G.; McEwan, P. A.; Barton, S. J.; Askari, J. A.; Craig, S. E.; Bella, J.; Humphries, M. J. Structure of an integrin-ligand complex deduced from solution X-ray scattering and site-directed mutagenesis. J. Biol. Chem. 2003, 278, 39993-39999.
22. (b) Takagi, J.; Strokovich, K.; Springer, T. A.; Walz, T. Structure of integrin alpha5beta1 in complex with fibronectin. EMBO J. 2003, 22, 4607-4615.
23. Smallheer, J. M.; Weigelt, C. A.; Woerner, F. J.; Wells, J. S.; Daneker, W. F.; Mousa, S. A.; Wexler, R. R.; Jadhav, P. K. Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds. Bioorg. Med. Chem. Lett. 2004, 14, 383-387.
24. αvβ3 sequence numbering was retrieved from the PBD database. Sequence numbering of α5 and β1 subunits started from the amino acids corresponding to the first residues of αv and β3 in the X-ray structure. First residues of α5 and β1 subunits were numbered as 1 and 55 according to the template numbering.
25. (a) Gottschalk, K. E.; Kessler, H. The structures of integrins and integrin-ligand complexes: implications for drug design and signal transduction. Angew. Chem., Int. Ed. 2002, 41, 3767-3774.
26. (b) Marinelli, L.; Lavecchia, A.; Gottschalk, K. E.; Novellino, E.; Kessler, H. Docking studies on αvβ3 integrin ligands: pharmacophore refinement and implications for drug design. J. Med. Chem. 2003, 46, 4393-4404.
27. Marinelli, L.; Gottschalk, K. E.; Meyer, A.; Novellino, E.; Kessler, H. Human integrin αvβ5: homology modeling and ligand binding. J. Med. Chem. 2004, 47, 4166-4177.
28. Humphries, M. J.; Symonds, E. J. H.; Mould, A. P. Mapping functional residues onto integrin crystal structures. Curr. Opin. Struct. Biol. 2003, 13, 236-243.
29. Yahalom, D.; Wittelsberger, A.; Mierke, D. F.; Rosenblatt, M.; Alexander, J. M.; Chorev, M. Identification of the principal binding site for RGD-containing ligands in the α(V)β(3) integrin: a photoaffinity cross-linking study. Biochemistry 2002, 41, 8321-8331.
30. Lommerse, J. P. M.; Price, S. L.; Taylor, R. IsoStar: a library of information about nonbonded interactions. J. Comput. Chem. 1997, 18, 758-774.
31. (a) Keenan, R. M.; Miller, W. H.; Lago, M. A.; Ali, F. E.; Bondinell, W. E.; Callahan, J. F.; et al. Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonists. Bioorg. Med. Chem. Lett. 1998, 8, 3165-3170.
32. (b) Kling, A.; Backfisch, G.; Delzer, J.; Geneste, H.; Graef, C.; Holzenkamp, U.; et al. Synthesis and SAR of N-substituted dibenzazepinone derivatives as novel potent and selective alpha(v)beta(3) antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 441-446.
33. (a) Müller, G.; Gurrath, M.; Kessler, H.; Timpl, R. Dynamic forcing, a method for evaluating activity and selectivity profiles of RGD (Arg-Gly-Asp) peptides. Angew. Chem., Int. Ed. Engl. 1992, 31, 326-328.
34. (b) Müller, G.; Gurrath, M.; Kessler, H. Pharmacophore refinement of gpIIb/IIa antagonists based on comparitive studies of antiadhesive cyclic and acyclic RGD peptides. J. Comput.-Aided Mol. Des. 1994, 8, 709-730.
35. Refinement and implication for drug design. J. Med. Chem. 2003, 46, 4393-4404.
36. Haubner, R.; Fisinger, D.; Kessler, H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angew. Chem., Int. Ed. Engl. 1997, 36, 137-1389.
37. Xiao, T.; Takagi, J.; Coller, B. S.; Wang, J.-H.; Springer, T. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004, 432, 59-67.
38. Thompson, J. D.; Higgins, D. G.; Gibson, T. J. Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22, 4673-4680.
39. Sali, A.; Potterton, L.; Yuan, F.; van Vlijmen, H.; Karplus, M. Evaluation of comparative modeling by MODELLER. Protein 1995, 23, 318-326.
40. SYBYL Molecular Modeling System, version 6.8; Tripos Associates: St. Louis, MO.
41. Head, J.; Zerner, M. C. A Broyden-Fletcher-Goldfarb-Shanno optimization procedure for molecular geometries. Chem. Phys. Lett. 1985, 122, 264-274.
42. Vinter, J. G.; Davis, A.; Saunders, M. R. Strategic approaches to drug design. 1. An integrated software framework for molecular modelling. J. Comput.-Aided Mol. Des. 1987, 1, 31-55.
43. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron 1980, 36, 3219-3228.
44. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
45. Accelrys, San Diego, CA.
46. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.